Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02208882 · ClinicalTrials.gov registry record · Phase 1

Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120

A Phase 1 study of Healthy Adult Volunteers, sponsored by Bristol-Myers Squibb.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT02208882: Completed Phase 1 study of Healthy Adult Volunteers, sponsored by Bristol-Myers Squibb.

NCT02208882 is a Phase 1 study of Healthy Adult Volunteers that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 24 participants, above the 18-participant average among 4 other Healthy Adult Volunteers trials with a reported enrollment target (33% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02208882, a Phase 1 study of Healthy Adult Volunteers, has completed, sponsored by Bristol-Myers Squibb.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to assess the safety, tolerability and effect on Midazolam pharmacokinetics of multiple oral doses of BMS-986120 in healthy subjects.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG Midazolam
  • DRUG BMS-986120

Study Locations (1)

Texas

  • Ppd Development, Lp - Austin

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2014-08
Est. Completion 2015-02
Phase Phase 1
Bristol-Myers Squibb

1,025 total trials

What the finished NCT02208882 record still lists

NCT02208882 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, above the 18-participant average among 4 other Healthy Adult Volunteers trials with a reported enrollment target (33% higher).

The record links to 1 condition, with Healthy Adult Volunteers appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02208882 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT02208882 about?

NCT02208882 is a clinical study titled "Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BMS-986120 in Healthy Subjects and the Effects of Co-Administration of Midazolam and BMS-986120". The purpose of this study is to assess the safety, tolerability and effect on Midazolam pharmacokinetics of multiple oral doses of BMS-986120 in healthy subjects.

What is the current status of trial NCT02208882?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2014-08. Estimated completion is 2015-02.

What conditions does trial NCT02208882 study?

This clinical trial studies the following conditions: Healthy Adult Volunteers.

What interventions are being tested in trial NCT02208882?

The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), BMS-986120 (DRUG).

Who is sponsoring clinical trial NCT02208882?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02208882 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy Adult Volunteers

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02208882, the US trial registry maintained by the National Library of Medicine. NCT02208882 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.